We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+6.48%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.7B
AUM Growth
+$120M
Cap. Flow
-$25.9M
Cap. Flow %
-0.96%
Top 10 Hldgs %
44.18%
Holding
152
New
13
Increased
22
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$17.5M
2
NVRO
NEVRO CORP.
NVRO
+$15.6M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$14.2M
4
NVS icon
Novartis
NVS
+$11.9M
5
BIIB icon
Biogen
BIIB
+$11.8M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.3M
2
MOH icon
Molina Healthcare
MOH
+$18.4M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.9M
4
PFE icon
Pfizer
PFE
+$11.2M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 91.69%
2 Real Estate 3.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$189M 7.01%
1,456,605
+90,000
+7% +$11M
GILD icon
2
Gilead Sciences
GILD
$163B
$179M 6.63%
2,530,131
– –
BIIB icon
3
Biogen
BIIB
$30.7B
$144M 5.33%
529,774
+44,800
+9% +$11.8M
AMGN icon
4
Amgen
AMGN
$209B
$118M 4.37%
684,824
– –
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$122B
$103M 3.81%
798,053
-235,450
-23% -$28.3M
JNJ icon
6
Johnson & Johnson
JNJ
$617B
$94.5M 3.5%
714,362
– –
MRK icon
7
Merck
MRK
$321B
$94.4M 3.5%
1,544,013
+288,143
+23% +$17.5M
REGN icon
8
Regeneron Pharmaceuticals
REGN
$77.4B
$92.2M 3.41%
187,666
– –
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$91.4M 3.38%
750,905
-45,000
-6% -$5.24M
INCY icon
10
Incyte
INCY
$24.9B
$87.3M 3.23%
693,275
– –
AGN
11
DELISTED
Allergan plc
AGN
$75.5M 2.8%
310,610
– –
VTRS icon
12
Viatris
VTRS
$20.7B
$62.2M 2.31%
1,603,112
+52,700
+3% +$2.02M
UNH icon
13
UnitedHealth
UNH
$383B
$57M 2.11%
307,476
+624
+0.2% +$109K
ABT icon
14
Abbott
ABT
$183B
$56M 2.08%
1,152,520
– –
MDT icon
15
Medtronic
MDT
$110B
$51.5M 1.91%
580,326
-32,704
-5% -$2.76M
ILMN icon
16
Illumina
ILMN
$31B
$48.4M 1.79%
286,771
-18,915
-6% -$3.27M
BMRN icon
17
BioMarin Pharmaceuticals
BMRN
$11.7B
$45.6M 1.69%
501,745
-4,100
-0.8% -$373K
JAZZ icon
18
Jazz Pharmaceuticals
JAZZ
$16.2B
$42.6M 1.58%
273,916
-57,495
-17% -$8.79M
SHPG
19
DELISTED
Shire pic
SHPG
$41.7M 1.54%
252,113
+20,700
+9% +$3.62M
LLY icon
20
Eli Lilly
LLY
$1.03T
$40.6M 1.5%
493,100
– –
TEVA icon
21
Teva Pharmaceuticals
TEVA
$41.2B
$33.7M 1.25%
1,015,758
– –
NVS icon
22
Novartis
NVS
$301B
$33.3M 1.23%
444,907
+167,246
+60% +$11.9M
CVS icon
23
CVS Health
CVS
$134B
$33.1M 1.23%
411,891
– –
HUM icon
24
Humana
HUM
$44B
$30M 1.11%
124,781
-29,019
-19% -$6.57M
PFE icon
25
Pfizer
PFE
$142B
$27.2M 1.01%
853,832
-354,778
-29% -$11.2M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Tekla Capital Management held 152 positions worth $2.7B, up 4.7% from $2.58B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Tekla Capital Management's Q2 2017 filing shows 13 new, 22 increased, 27 reduced and 8 closed positions. Its largest new stake was NEVRO CORP.: 194,621 shares worth $14.5M. The largest sale was Vertex Pharmaceuticals, an estimated $28.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2017 buy was NEVRO CORP.: 194,621 shares worth $14.5M.
  • Tekla Capital Management added most to Merck in Q2 2017, an estimated $17.5M increase.
  • Tekla Capital Management's biggest Q2 2017 reduction was Vertex Pharmaceuticals, cutting an estimated $28.3M.
  • Tekla Capital Management fully exited Molina Healthcare in Q2 2017, selling an estimated $18.4M.
  • Tekla Capital Management's ten largest holdings make up 44% of its $2.7B portfolio in Q2 2017.
  • Tekla Capital Management opened 13 new positions and closed 8 in Q2 2017.
  • Tekla Capital Management's portfolio value rose 4.7% quarter-over-quarter to $2.7B.

Based on Tekla Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.